These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
602 related articles for article (PubMed ID: 33958297)
1. Assessment of Total, PTEN Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297 [TBL] [Abstract][Full Text] [Related]
2. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355 [TBL] [Abstract][Full Text] [Related]
3. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425 [TBL] [Abstract][Full Text] [Related]
4. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304 [TBL] [Abstract][Full Text] [Related]
5. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549 [TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885 [TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442 [TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Zhu Y; Silberstein JL; Taylor MN; Maughan BL; Denmeade SR; Pienta KJ; Paller CJ; Carducci MA; Eisenberger MA; Luo J J Clin Oncol; 2017 Jul; 35(19):2149-2156. PubMed ID: 28384066 [TBL] [Abstract][Full Text] [Related]
9. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641 [TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238 [TBL] [Abstract][Full Text] [Related]
11. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168 [TBL] [Abstract][Full Text] [Related]
12. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Halabi S; Guo S; Park JJ; Nanus DM; George DJ; Antonarakis ES; Danila DC; Szmulewitz RZ; McDonnell DP; Norris JD; Lu C; Luo J; Armstrong AJ Clin Cancer Res; 2024 Mar; 30(6):1152-1159. PubMed ID: 38236581 [TBL] [Abstract][Full Text] [Related]
13. Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. Maillet D; Allioli N; Peron J; Plesa A; Decaussin-Petrucci M; Tartas S; Ruffion A; Crouzet S; Rimokh R; Gillet PG; Freyer G; Vlaeminck-Guillem V Eur Urol Oncol; 2021 Aug; 4(4):609-617. PubMed ID: 31676281 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Onstenk W; Sieuwerts AM; Kraan J; Van M; Nieuweboer AJ; Mathijssen RH; Hamberg P; Meulenbeld HJ; De Laere B; Dirix LY; van Soest RJ; Lolkema MP; Martens JW; van Weerden WM; Jenster GW; Foekens JA; de Wit R; Sleijfer S Eur Urol; 2015 Dec; 68(6):939-45. PubMed ID: 26188394 [TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Brown LC; Halabi S; Schonhoft JD; Yang Q; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Barnett ES; Carbone EA; Zhao JL; Healy P; Anand M; Gill A; Jendrisak A; Berry WR; Gupta S; Gregory SG; Wenstrup R; Antonarakis ES; George DJ; Scher HI; Armstrong AJ Clin Cancer Res; 2021 Jul; 27(14):4077-4088. PubMed ID: 33820782 [TBL] [Abstract][Full Text] [Related]
16. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest. Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648 [TBL] [Abstract][Full Text] [Related]
17. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. Armstrong AJ; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Berry WR; Zhang T; Harrison MR; Lu C; Chen Y; Galletti G; Schonhoft JD; Scher HI; Wenstrup R; Tagawa ST; Antonarakis ES; George DJ; Halabi S JCO Precis Oncol; 2020; 4():. PubMed ID: 33154984 [TBL] [Abstract][Full Text] [Related]
18. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Markowski MC; Frick KD; Eshleman JR; Luo J; Antonarakis ES Prostate; 2016 Dec; 76(16):1484-1490. PubMed ID: 27404039 [TBL] [Abstract][Full Text] [Related]
19. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263 [TBL] [Abstract][Full Text] [Related]
20. AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis. Pacheco-Orozco RA; Montealegre-Páez L; Cayol F; Martínez-Gregorio H; Oliver J; Frecha C; Vaca-Paniagua F; Perdomo S Oncologist; 2020 Dec; 25(12):e1990-e1995. PubMed ID: 32721059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]